393 related articles for article (PubMed ID: 30726931)
1. Cardioprotection in cancer therapy: novel insights with anthracyclines.
Raber I; Asnani A
Cardiovasc Res; 2019 Apr; 115(5):915-921. PubMed ID: 30726931
[TBL] [Abstract][Full Text] [Related]
2. [Cardiotoxicity of anthracyclines].
Costache II; Petriş A
Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
[TBL] [Abstract][Full Text] [Related]
3. Heart Failure in Relation to Anthracyclines and Other Chemotherapies.
Agunbiade TA; Zaghlol RY; Barac A
Methodist Debakey Cardiovasc J; 2019; 15(4):243-249. PubMed ID: 31988684
[TBL] [Abstract][Full Text] [Related]
4. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
Ghigo A; Li M; Hirsch E
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
[TBL] [Abstract][Full Text] [Related]
5. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
Vejpongsa P; Yeh ET
J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?
Dempke WCM; Zielinski R; Winkler C; Silberman S; Reuther S; Priebe W
Eur J Cancer; 2023 May; 185():94-104. PubMed ID: 36966697
[TBL] [Abstract][Full Text] [Related]
7. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Chung WB; Youn HJ
Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
Sawyer DB; Peng X; Chen B; Pentassuglia L; Lim CC
Prog Cardiovasc Dis; 2010; 53(2):105-13. PubMed ID: 20728697
[TBL] [Abstract][Full Text] [Related]
10. Anthracycline cardiotoxicity in childhood.
Ruggiero A; Ridola V; Puma N; Molinari F; Coccia P; De Rosa G; Riccardi R
Pediatr Hematol Oncol; 2008 Jun; 25(4):261-81. PubMed ID: 18484471
[TBL] [Abstract][Full Text] [Related]
11. Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.
Sadurska E
Pediatr Cardiol; 2015 Aug; 36(6):1112-9. PubMed ID: 25939787
[TBL] [Abstract][Full Text] [Related]
12. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline cardiotoxicity.
Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.
Barry E; Alvarez JA; Scully RE; Miller TL; Lipshultz SE
Expert Opin Pharmacother; 2007 Jun; 8(8):1039-58. PubMed ID: 17516870
[TBL] [Abstract][Full Text] [Related]
15. Pediatric quality of life in long-term survivors of childhood cancer treated with anthracyclines.
Ryerson AB; Wasilewski-Masker K; Border WL; Goodman M; Meacham L; Austin H; Marchak JG; Mertens AC
Pediatr Blood Cancer; 2016 Dec; 63(12):2205-2211. PubMed ID: 27442487
[TBL] [Abstract][Full Text] [Related]
16. [Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
Vasyuk YA; Shkolnik EL; Nesterov VV; Shkolnik LD; Varlan GV
Kardiologiia; 2016 Dec; 56(12):72-79. PubMed ID: 28290807
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular disease in survivors of childhood cancer.
Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients.
Bassareo PP; Monte I; Romano C; Deidda M; Piras A; Cugusi L; Coppola C; Galletta F; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e55-e63. PubMed ID: 27755243
[TBL] [Abstract][Full Text] [Related]
19. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
Wu V
J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity: anthracyclines and long term cancer survivors.
Patanè S
Int J Cardiol; 2014 Oct; 176(3):1326-8. PubMed ID: 25129289
[No Abstract] [Full Text] [Related]
[Next] [New Search]
